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Abstract:
NF-κB is a key regulator of inflammation and cancer progression, with important role in leukemogenesis. Despite therapeutic potential, targeting
NF-κB using pharmacologic inhibitors proved challenging. Here, we describe a myeloid cell-selective NF-κB inhibitor using miR146a mimic
oligonucleotide conjugated to a scavenger receptor (SR)/Toll-like receptor 9 (TLR9) agonist (C-miR146a). Unlike an unconjugated miR-146a, C-
miR146a was rapidly internalized and delivered to cytoplasm of target myeloid cells and leukemic cells. C-miR146a reduced expression of classic
miR-146a targets, IRAK1 and TRAF6, thereby blocking NF-κB activation in target cells. Intravenous injections of C-miR146a mimic to miR-
146-deficient mice prevented excessive NF-κB activation in myeloid cells, thereby alleviating myeloproliferation and mice hypersensitivity to
bacterial challenge. Importantly, C-miR146a showed efficacy in dampening severe inflammation in clinically relevant models of chimeric antigen
receptor (CAR) T-cell-induced cytokine release syndrome (CRS). Systemic administration of C-miR146a oligonucleotide alleviated human
monocyte-dependent release of IL-1 and IL-6 in xenotransplanted B-cell lymphoma model without affecting CD19-specific CAR T-cell antitumor
activity. Beyond anti-inflammatory functions, miR146a is a known tumor suppressor commonly deleted or expressed at reduced levels in human
myeloid leukemia. Using TCGA AML dataset, we found inverse correlation of miR-146 levels with NF-κB-related genes and with patients’ survival.
Correspondingly, C-miR146a induced cytotoxic effects in human MDSL, HL-60 and MV4-11 leukemia cells in vitro. The repeated intravenous
administration of C-miR146a inhibited expression of NF-κB target genes and thereby thwarted progression of disseminated HL-60 leukemia. Our
results demonstrate potential of using myeloid cell-targeted miR146a mimics for treatment of inflammatory and myeloproliferative disorders.
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KEY POINTS 
■ Synthetic C-miR146a mimic inhibits inflammatory and tumorigenic NF-κB activity in macrophages and 
myeloid leukemia in vitro and in vivo. 
■ C-miR146a alleviates monocyte-mediated cytokine storm without affecting CD19-specific CAR T-cell 
activity against B-cell lymphoma.   
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ABSTRACT 
NF-κB is a key regulator of inflammation and cancer progression, with important role in leukemogenesis. 
Despite therapeutic potential, targeting NF-κB using pharmacologic inhibitors proved challenging. Here, we 
describe a myeloid cell-selective NF-κB inhibitor using miR146a mimic oligonucleotide conjugated to a 
scavenger receptor (SR)/Toll-like receptor 9 (TLR9) agonist (C-miR146a). Unlike an unconjugated miR-
146a, C-miR146a was rapidly internalized and delivered to cytoplasm of target myeloid cells and leukemic 
cells. C-miR146a reduced expression of classic miR-146a targets, IRAK1 and TRAF6, thereby blocking NF-
κB activation in target cells. Intravenous injections of C-miR146a mimic to miR-146-deficient mice prevented 
excessive NF-κB activation in myeloid cells, thereby alleviating myeloproliferation and mice hypersensitivity 
to bacterial challenge. Importantly, C-miR146a showed efficacy in dampening severe inflammation in 
clinically relevant models of chimeric antigen receptor (CAR) T-cell-induced cytokine release syndrome 
(CRS). Systemic administration of C-miR146a oligonucleotide alleviated human monocyte-dependent 
release of IL-1 and IL-6 in xenotransplanted B-cell lymphoma model without affecting CD19-specific CAR T-
cell antitumor activity. Beyond anti-inflammatory functions, miR146a is a known tumor suppressor 
commonly deleted or expressed at reduced levels in human myeloid leukemia. Using TCGA AML dataset, 
we found inverse correlation of miR-146 levels with NF-κB-related genes and with patients’ survival.  
Correspondingly, C-miR146a induced cytotoxic effects in human MDSL, HL-60 and MV4-11 leukemia cells 
in vitro. The repeated intravenous administration of C-miR146a inhibited expression of NF-κB target genes 
and thereby thwarted progression of disseminated HL-60 leukemia. Our results demonstrate potential of 
using myeloid cell-targeted miR146a mimics for treatment of inflammatory and myeloproliferative disorders.  
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INTRODUCTION  
MicroRNAs (miRNAs) are small non-coding RNAs that control expression of a broad set of target genes 
based on sequence complementarity. By binding to the target mRNA’s 3’ untranslated regions (3’UTR), 
miRNAs regulate gene expression and enable control of multiple gene targets within the same or distinct 
signaling pathways.1,2 Many miRNAs are dysregulated in cancer, cardiovascular and autoimmune 
diseases.3 Genomic mutations, deletion, or changes in the key enzymes in miRNA biogenesis may all lead 
to alterations in miRNA levels.4,5 Genome-wide miRNA screening of leukemia-associated loci identified 
miR146a as major mediator of the chromosome-5q deletion myelodysplastic syndrome, del(5q) MDS, and 
acute myeloid leukemia (AML).6-8 The reduced miR-146a expression contributes to the development of 
del(5q) MDS and progression to AML through IRAK1- and TRAF6-dependent activation of NF-κB.9,10 In non-
malignant myeloid cells, such as monocytes, decreased miR-146a levels result in expression of IL-6 and 
other proinflammatory mediators implicated in the pathogenesis of autoimmune diseases and cancers.11-13 
The miR-146a dysregulation and IL-6 elevation in hematopoietic stem/progenitor and myeloid cells is also 
associated with many autoinflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, 
type II diabetes, Sjogren’s syndrome and endotoxemia-related cytokine storm.14 While the role of miR146a 
is yet unclear, the NF-κB-mediated release of IL-6 from monocyte was also shown responsible for cytokine 
release syndrome (CRS), a serious adverse effect of CAR T-cell therapies.12,15 Due to lack of 
pharmacologic NF-κB inhibitors, synthetic miRNA146a mimics are an attractive opportunity for 
immunomodulation or elimination of tumorigenic signaling. However, the effective delivery of miRNA 
therapeutics is challenging, complicated by safety concerns and potential off-target effects.2,16 Several types 
of miRNA delivery vehicles, including liposomes, lipid nanoparticles, dendrimers or hydrogels were tested 
before.17-19 Only a few of synthetic miRNA mimics, including anti-fibrotic and TGFβ-targeting miR-
29/Remlarsen, progressed to initial clinical testing.19 Here, we describe an original approach for the targeted 
delivery of chemically-modified miR146a mimic to myeloid cells and verify miR146a mimic activity in models 
of inflammatory and myeloproliferative diseases.  
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METHODS 
Mice and in vivo studies 
All animal experiments were following institutional guidance and approved protocols from the Institutional 
Animal Care and Use Committee. C57BL/6, BALB/c mice 6-8 weeks of age were purchased from the 
National Cancer Institute, female C.B-Igh-1b/GbmsTac-Prkdcscid-LystbgN7 (SCID-Beige) mice were from 
Taconic, NOD/SCID/IL-2RgKO (NSG) and NSG Tg(IL3,CSF2,KITLG)1Eav/MloySzJ  (SGM3) mice were 
from Jackson Laboratory. miR-146a−/− and LyzM-Cre/miR-146afl/fl mice9,20 were bred and housed in 
Laboratory Animal Resources facility at Caltech.  
 
C-miR146a synthesis 
The C-miR146a conjugates were synthesized in the DNA/RNA Synthesis Core (COH) by linking CpG-D19 
to miR-146a passenger strands as described.21 These were hybridized with complementary guide strands 
of mature miR-146a creating chimeric C-miR146a mimic. The single stranded sequences are listed below 
(x = C3-unit; asterisks = phosphorothioation; underline = 2’O-methylation): 
C-miR146a passenger:  
5’ G*G*TGCATCGATGCAGG*G*G*G*G-xxxxx-CCCAUGGAAUUCAGUUCUCAAA 3’. 
miR146a guide:  
5’ UGAGAACUGAAUUCCAUGGGUU 3’. 
C-scrRNA passenger: 
5’ G*G*TGCATCGATGCAGG*G*G*G*G -xxxxx-AUUUAGCCUUAAUACACGCCAA 3’ 
scrRNA guide: 
5’ GGCGUGUAUUAAGGCUAAAUCU 3’ 
For internalization studies, the miR146a guide strand was labeled on 3’ end using Cy3 fluorochrome. 
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RNA-binding protein immunoprecipitation 
The RNA-binding protein immunoprecipitation/RIP was performed using Magna RIP kit (Millipore) according 
to manufacturer’s instructions. Details described in the Supplemental Methods.  
 
In vivo bio-distribution 
miR-146a−/− mice or syngeneic Cbfb/Myh11/Mpl mouse leukemia-bearing C57BL/6 mice were injected retro-
orbitally with 2.5-20mg/kg C-miR146a, C-miR146aCy3 or miR146aCy3 as described before.22 At indicated 
times, mice were euthanized to collect organs for flow cytometry, qPCR or Western blot analysis. EasySep 
PE-positive selection kits (Stemcell) were used for cell subset enrichment.    
 
Listeria monocytogenes studies 
105 c.f.u. of Listeria monocytogenes (strain-10,403/serotype-1) was injected to each WT C57BL/6 or LyzM-
Cre/miR-146afl/fl mice using retro-orbital injections. Mice were treated every day using 5mg/kg C-miR146a or 
C-scrRNA (negative control) for three days before and three days after infection. The mice were euthanized, 
various organs were collected for further analysis. 
 
Cytokine release syndrome models 
For in vitro studies, mock or CD19 CAR T cells from four donors were cultured with target Nalm6 leukemia 
with or without CD14+ monocytes from same donor. Healthy donors' PBMCs were collected according to 
Declaration of Helsinki. The co-cultured cells were treated with C-miR146a or C-scrRNA (500nM) for 2 days. 
After 48h, supernatants were collected and IL-1 and IL-6 levels were analyzed using ELISA (Thermo Fisher). 
In vivo CRS studies used female SCID-Beige mice  
injected using 3106 RajiGFP/Luc cells, following with intraperitoneal injections of C-miR146a (5mg/kg) or PBS 
daily for three days before transfer of 12.5106 mock-transfected or CD19-specific CAR-T-cells described 
before.15,23,24  
 
Human AML xenotransplants  
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NSG-SGM3 mice were injected intravenously with 2106 of HL-60LUC cells and tumor progression was 
monitored using BLI/AmiX (Spectral Instruments). Mice were injected retro-orbitally with 10mg/kg of C-
miR146a or C-scrRNA every other day. Total RNA was isolated from bone marrow cells and analyzed using 
RT2 Profiler PCR Arrays (Qiagen). 
 
Gene expression analysis 
The overall survival analysis was conducted using R package survival (vs.2.44.1.1). Log-rank statistics were 
applied to identify the optimal cut-point for transforming the continuous variable of gene expression into 
categorical high and low expression groups in a survfit model, using the cutp function of the R package 
survMisc (vs.0.5.5).  
 
Statistics  
Unpaired t test was used to calculate two-tailed P value to estimate statistical significance between two 
treatment groups. One- or two-way ANOVA plus Bonfeerroni post-test assessed differences between 
multiple groups or in tumor growth kinetics, respectively. Statistically significant P values were indicated in 
figures compared to untreated or PBS groups. Data analyzed using Prism software v.7 (GraphPad).  
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RESULTS 
Targeted delivery of functional miR-146a mimic into myeloid cells and B-cells 
To overcome challenges in the efficient and cell-selective delivery of miR-146a, we modified the scavenger 
receptor (SR)/Toll-like receptor 9 (TLR9)-targeting platform originally developed for transfer of 25/27-mer 
Dicer-substrate siRNA.21 The double-stranded miR-146a was conjugated through 5’ end of the passenger 
strand to the 3’ end of a single-stranded, partly phosphorothioated oligodeoxynucleotide (CpG ODN) using 
a synthetic carbon linker. The specific type-A CpG ODN sequence of the conjugate was selected for 
monocytes/myeloid cell specificity25 and poor ability to activate NF-B and its downstream IL-6 and IL-10 
targets.26 To ensure the maximum activity and target specificity, the miR-146a was chemically modified for 
nuclease resistance by a 2’O-methyl-modification in the 3’ end of passenger strand (Figure 1A). This design 
significantly improved serum stability of the C-miR-146a conjugate without impacting activity. Compared to 
miR-146a (T1/2~1h), the conjugated C-miR146a had 34h half-life in human serum (Figure 1B and 
Supplemental Fig.S1). The C-miR146aCy3 was rapidly internalized by primary human immune cells and 
mouse RAW264.7 macrophages (Figure 1C) or splenocytes (Supplemental Fig.S2) within 1h of incubation, 
without any transfection reagents. Compared to the unconjugated miR146aCy3, C-miR146aCy3 was also 
efficiently taken up by human MDSL or HL60 myeloid leukemia cells, Raji Burkitt’s lymphoma cells but not 
human T-cell leukemia TAIL7 cells (Figure 1C). The uptake of C-miR146a depended on the scavenger 
receptor A- and clathrin-mediated endocytosis, as verified using internalization inhibitors, specifically 
dextran sulfate, fucoidan and cadaverine (Supplemental Fig.S3). TLR9 commonly expressed by myeloid 
and B-cell malignancies, including tested myeloid leukemia and B-cell lymphoma cells (Supplemental Fig.S 
4).26 Confocal microscopy showed that C-miR146a localized to the cytosol of target cells within 1h, while 
miR-146a alone was undetectable (Figure 1D). To inhibit target mRNAs, the miRNA guide strand must bind 
Argonaute-2 (Ago2) protein within the RNA-induced silencing complex (RISC). To assess whether the guide 
strand of C-miR146a was successfully loaded onto the RISC, we performed RNA-binding protein 
immunoprecipitation (RIP) using Ago2-specific antibodies (Figure 1E). In fact, the level of Ago2-bound miR-
146a guide strand increased several fold in mouse RAW264.7 macrophages incubated with the C-miR146a 
but not with miR-146a. This effect was even more prominent in primary mouse splenocytes derived from 
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miR-146a–/– mice (Figure 1E). These results indicated that the C-miR146a allows for the delivery of 
functional miR-146a to human and mouse myeloid target cells.        
 
C-miR146a mimic targets upstream regulators of NF-κB signaling 
MiR-146a targets IRAK1 and TRAF6, the critical upstream regulators of NF-κB signaling.10 We used 3’-
UTR-luciferase reporter assays to verify whether C-miR146a can alter IRAK1 and TRAF6 expression. As 
shown in Figure 2A, C-miR146a conjugate reduced IRAK1 and TRAF6 3’-UTR-luciferase reporter activities 
in sequence-specific manner as verified by mutating 3’-UTR sequences (Figure 2A). Neither miR-146a 
alone nor negative control scrambled RNA (C-scrRNA) affected these 3’-UTR-luciferase reporters. 
Moreover, C-miR146a, but not the control oligonucleotides, reduced IRAK1 and TRAF6 protein levels in 
mouse RAW264.7 macrophages but only IRAK1 in human MDSL cells (Figure 2B). Lack of TRAF6 
inhibition by C-miR146a is likely related to a mutation in one of miR-146a binding sites in TRAF6 3’UTR in 
human MDSL cells (Supplemental Fig.S5). Activated NF-κB translocates to the nucleus, thus we examined 
the effect of C-miR146a on the localization of NF-κB in LPS-treated RAW264.7 cells expressing NF-κB/p65-
eGFP fusion protein.27 Confocal microscopy confirmed that C-miR146a, but not C-scrRNA, efficiently 
blocked the nuclear translocation of NF-κB (Figure 2C). Correspondingly, the C-miR146a reduced the NF-
κB DNA-binding activity in nuclear extracts from RAW264.7 and MDSL cells as measured using gelshift 
assays (Figure 2D). These C-miR146a effects reduced LPS-induced transcriptional NF-κB activity in 
RAWBlue macrophages (Figure. 2E) and secretion of IL-6 by parental RAW264.7 cells (Figure 2F).  
For an additional verification that the observed effects sequence-specific, we used analogical approach to 
deliver miR146a-targeting antisense oligonucleotide, C-anti-miR146a (Supplemental Fig.S6A).28 C-anti-
miR146a showed similar cell-selectivity as C-miR146a mimic (Supplemental Fig.S6B) but opposite 
biological activity. C-anti-miR146a knocked-down miR-146a in mouse splenocytes and myeloid cells 
(Supplemental Fig.S6C), thereby upregulating IRAK1 and TRAF6 3’UTR activities (Supplemental Fig.S6DE), 
NF-B DNA-binding (Figure 2D) and nuclear translocation (Supplemental Fig.S6F). Taken together, the 
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flexibility of our strategy permits positive or negative regulation of NF-κB activity using SR/TLR9-mediated 
miR-146a mimic or antisense delivery, respectively. 
 
Systemic C-miR146a mimic delivery restored control over IRAK1 and TRAF6 in miR-146a-deficient 
myeloid cells in vivo   
Treatment of NF-κB-related disorders requires efficient delivery of miR146a mimic to target myeloid cells in 
various organs. To directly quantify the dose- and time-dependent biodistribution of C-miR146a mimic in the 
absence of endogenous miR146a, we used the real-time qPCR to detect miR-146a guide-strand in various 
organs of miR-146a-deficient mice.9 Our initial pharmacokinetic analysis found that C-miR146a reaches 
maximum plasma level ~30 min after intravenous injection, with 144 min circulatory half-life (Supplemental 
Fig.S7). Consistently, we found dose-dependent accumulation of miR-146a guide-strand in bone-marrow, 
spleens and lymph nodes of miR-146a–/– mice following IV-injection of C-miR146a (Figure 3A). In 2.5-
20mg/kg dose-range, C-miR146a delivered miR-146a-5p guide-strand preferentially to CD11b+ myeloid 
cells from bone-marrow (Figure 3B). For more precise identification of target cells, we injected IV 
fluorescently-labeled C-miR146aCy3 or miR146aCy3 (5mg/kg) into AML-bearing mice and analyzed their 
cellular uptake after 3h using flow cytometry. C-miR146aCy3 was internalized by ~30-50% of various myeloid 
cells and leukemic cells, ~20% of long-term HSCs, minimally by B and NK cells but not by T cells (Figure 
3C). As expected, cellular uptake of miR146aCy3 alone was negligible. Next, we compared the miR-146a 
levels in oligonucleotide-treated miR-146a–/– mice to the untreated wild-type (WT) mice to quantify the 
relative miR-146a restoration in specific immune cell populations. As shown in the Figure 3D, the single 
injection of 5mg/kg C-miR146a to miR-146a–/– mice replaced ~61% and ~53% of WT miR-146a levels in 
bone marrows and spleens, respectively. MiR-146a was restored to ~47%, ~28% and ~5% of the WT levels, 
in splenic CD11b+ myeloid cells, CD19+ B-cells and CD3+ T-cells, respectively (Figure 3E), confirming 
preferential myeloid cell-targeting. Finally, we have tested whether partial restoration of miR-146a will have 
sufficient biological activity to inhibit target IRAK1 and TRAF6 proteins. In fact, within 12-24h after a single 
IV injection of C-miR146a (5mg/kg), both IRAK1 and TRAF6 were reduced close to the WT levels, returning 
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to the baseline after 2-3 days (Figure 3F). These results indicate that systemic delivery of C-miR146a using 
relatively low dosing can transiently restore levels and full biological activity of miR-146a in target myeloid 
cells in vivo. 
 
C-miR146a abrogates myeloproliferation and exaggerated inflammatory responses in miR146a-
deficient mice  
Expansion of myeloid cells is one of the critical phenotypic features of the miR-146a-deficient mice.29 
Compared to WT mice, bone marrow-derived macrophages (BMDMs) from miR-146a-deficient mice show 
enhanced proliferation accompanied by elevated expression of colony–stimulating factor–1 receptor 
(CSF1R).30 Therefore, we examined whether delivery of C-miR146a to miR-146a–/– BMDMs prevents the 
aberrant myeloproliferation. In fact, the C-miR146a but not C-scrRNA treatment reduced proliferative rate of 
miR-146a–/– BMDMs close to the WT BMDMs (Figure 4A). Together with the reduced proliferation, the 
elevated cell surface levels of CSF1R on miR-146a–/– BMDMs were reduced by C-miR146a to baseline WT 
levels (Figure 4B). Consistently, repeated two-week C-miR146a treatment of aged miR-146a–/– mice 
reduced the expansion of immature CD11b+Gr1+ myeloid cells, together with their proliferation and CSF1R 
expression on macrophages (Figure 4C-E).  
Next, we examined whether miR146a mimic delivery can attenuate the exaggerated inflammatory response 
to a systemic bacterial endotoxin challenge resulting from the miR-146a ablation.30 Age- and gender-
matched WT and miR-146a–/– mice were injected with a sub-lethal dose of LPS, and the plasma levels of 
pro-inflammatory cytokines, IL-6 and TNF-α, were measured using ELISA. As expected, LPS induced a 
higher and more prolonged cytokine response in miR-146a–/– mice than in WT mice, peaking at 2-6h before 
returning to baseline at 24h. In contrast, C-miR146a treatment reduced IL-6 and TNF-α upregulation in miR-
146a–/– mice at both 2 and 6h compared to C-scrRNA control treatment (Figure. 4F). The effect of C-
miR146a on the inflammatory cytokine secretion in WT mice was minimal, indicating the adequate negative 
control of cytokine production by the endogenous miR146a. Following on these results, we used mice with 
the myeloid cell-specific miR-146a ablation (LyzM-Cre/miR-146afl/fl) to assess the effect of miR-146a 
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restoration on the IL-6-controlled response to a bacterial infection with Listeria monocytogenes.20,31,32 Both 
WT and miR-146afl/fl mice were injected daily with C-miR146a or control C-scrRNA (5mg/kg) starting 3 days 
before the sublethal infection with L. monocytogenes. The C-miR146a treatment interfered with the bacterial 
clearance in miR-146a-deficient and WT mice increasing bacterial burden in liver and spleen (Figure 4G 
and Supplemental Fig.S8A). The reduced bacterial load in control-treated miR-146afl/fl mice correlated with 
weight loss (Figure 4H) and elevated plasma levels of IL-6 (Figure 4I). All these effects of miR146a-deletion 
were completely alleviated by C-miR146a treatment. Finally, miR-146a restoration decreased the expansion 
of CD11b+ myeloid cells, including Gr1+ granulocytes, in blood and spleen of control miR-146afl/fl mice 
(Figure 4J and Supplemental Fig.S8B). Taken together, our results indicate that myeloid cell-targeted miR-
146a restoration using C-miRNA mimic can reverse the key phenotypic features of miR-146a-deletion in 
mice. Noteworthy, we have not observed significant effect of C-miRNA mimic on other immune cell 
populations in WT mice, such as DCs, B cells or NK cells, even after repeated two-week daily IV injections 
(Supplemental Fig.S9-10). Finally, our C-miR146a two-week dose-escalation study (5-20mg/kg/day) did not 
find evidence of toxicities to hematopoietic cells or organ gross abnormalities (Supplemental Fig.S11).      
 
Monocyte-targeted miR146a delivery alleviates cytokine release syndrome triggered by CD19 CAR 
T-cells without compromising antitumor effects  
CAR T-cell immunotherapy has emerged as a revolutionary treatment for various hematologic cancers but 
many patients experience severe side effects of CRS.23,33 Recent studies linked CRS to CAR T-cell-
dependent activation of CD40 signaling in monocytes/macrophages, thereby inducing IL-1 and IL-6, the key 
cytokine storm mediators. While CD40 triggers canonical and non-canonical NF-B signaling, it does not 
upregulate miR-146a levels.29 Thus, we tested whether delivery of miR-146a mimic will dampen pro-
inflammatory effects of human monocytes induced by the CD19-specific CAR T-cells. Predictably, CD19 
CAR T-cells showed low uptake of fluorescently-labeled C-miR146aCy3 compared to monocytes 
(Supplemental Fig.S12A). C-miR146a did not affect CAR T-cell viability or cytotoxicity against target CD19+ 
Nalm6 leukemia (Figure 5A). Next, we tested C-miR146a in a three-component CRS model co-culturing in 
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vitro: CD19+ Nalm6 cells with CD19-specific CAR T-cells (generated from four different donors’ PBMCs) and 
donor-matched CD14+ monocytes (Figure 5B). The upregulation of IL-1 and IL-6 depended on the presence 
of monocytes and was induced only by CD19+ leukemia-specific and not mock-transfected CAR T-cells 
(Figure 5B). Importantly, C-miR146a reduced IL-1 secretion by half, while bringing IL-6 levels close to 
baseline compared to control treatments. Similar results were obtained using THP-1 monocyte-like cells 
instead of primary monocytes (Supplemental Fig.S12B-C).  
To further confirm that the combination of C-miR146a with CD19 CAR T-cells has potential for alleviating 
CRS-related toxicities, we adopted a model of CAR T-cell-induced CRS in human CD19+ Raji B-cell 
lymphoma in partly immunodeficient SCID-Beige mice, similar as recently published.15 Mice with heavy 
intraperitoneal lymphoma burden develop CRS and acute inflammation within 3 days after CD19 CAR T-cell 
injection (Figure 5C). Mice were treated using C-miR146a or control vehicle 3 days before CAR T-cell 
transfer. As shown in Figure 5DE, the C-miR146a did not interfere with the CAR T-cell mediated inhibition of 
lymphoma progression. However, the C-miR146a mimic doubled the amount of endogenous miR146a in 
target peritoneal myeloid cells (Figure 5F). As a result, we observed that C-miR146a dramatically reduced 
major CRS-related cytokines, IL-6 and G-CSF, likely derived from mouse monocytes in this model as 
suggested by others (Figure. 5G).15 Our findings underscore the potential of using C-miR146a mimic to 
alleviate adverse effects of CD19 CAR T-cell therapy without impeding on-target therapeutic effects. 
 
C-miR146a targets NF-κB signaling and inhibits del(5q) leukemia progression  
Low expression of miR-146a located on chromosome 5q has been reported in both MDS and AML since 
del(5q) aberrations are common in high-risk leukemia.7 However, constitutive activation of NF-κB survival 
signaling is not limited to del(5q) MDS/AML and occurs in up to 40% of AML.34 We tested C-miR-146a 
mimic effect on viability of HL-60, MDSL del(5q) leukemia cells and also FLT3ITD+/N(5q) MV4-11 AML cells, 
which all have been found sensitive to small molecule NF-B inhibitors (Supplemental Fig.S13). As shown 
in Figure 6A, C-miR146a induced cell death in all three models, although most effectively against miR-146a-
deficient MDSL and HL-60 cells. In initial testing, we confirmed that local delivery of C-miR146a into 
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subcutaneously engrafted leukemia models effectively inhibited growth of both HL-60 (Supplemental 
Fig.S14A) and MDSL (Supplemental Fig.S14B). Next, we examined the efficacy of systemic C-miR146a 
administration (10mg/kg) against disseminated HL-60 leukemia. As shown in Figure 6B-D, compared to 
controls, C-miR146a reduced AML progression and thereby significantly prolonged mice survival. Focused 
gene expression analysis of a panel of 84 NF-B-related genes confirmed that C-miR146a downregulated 
key elements of NF-B signaling in HL-60 cells, such as RELA, MYD88, NFKB1/2, TRAF3, TRAF6 or 
mediators IL1B and TNF (Figure 6E and Supplemental Fig.S15). Altogether, these results demonstrate the 
direct antitumor effect of C-miR146a both in vitro and in vivo, against miR-146a deficient MDS/AML likely 
through the inhibition of NF-B-mediated survival signaling. These conclusions are also supported by 
analysis of TCGA dataset from 164 AML patients. As expected, low miR-146a expression was associated 
with worse overall patients’ survival (Figure 6F). The gene set enrichment analysis (GSEA) indicated 
significant inverse correlation of miR-146a levels in AML with two different sets of NF-B-related genes, 
including IRAK1, NFKB1, NFKB2 but not TRAF6 (Figure 6G-H and Supplemental Fig.S16). Overall, these 
results underscore therapeutic potential of C-miR146a for treatment of del(5q) MDS/AML and potentially 
other NF-B-dependent types of leukemia.  
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DISCUSSION 
In this study, we demonstrate the feasibility of systemic delivery of miRNA mimic specifically to human and 
mouse myeloid cells for therapeutic modulation of their immune activity or neoplastic growth. The C-
miR146a injected intravenously restored miR-146a-5p in target myeloid cells to levels sufficient for complete 
elimination of exacerbated NF-κB activity in miR-146a–/– mice, thereby preventing the exaggerated 
inflammatory responses and aberrant myeloproliferation. Our miR146a mimic delivery strategy proved 
effective also in human models of NF-κB-driven inflammation and in myeloid leukemia (MDS/AML). 
Importantly, unlike standard anti-inflammatory strategies, such as steroid hormones, the myeloid cell-
specific miR146a mimic delivery proved effective without interfering with antitumor activity of CAR T-cells or 
any signs of toxicity even in repeated, long-term administration.  
Despite of broad clinical potential, only few miRNA therapeutics entered clinical trials and the majority 
represented antisense molecules (anti-miRs or antagomirs), which as single-stranded oligonucleotides 
proved easier to optimize for in vivo use.19,35 One of the best example is targeting lymphoma cell addiction 
to oncogenic miR-155.36 In contrast, the therapeutic replacement/restoration of tumor suppressor miRNAs 
proved challenging. The chemical modification of miRNA to ensure nuclease-resistance can interfere with 
intracellular processing, RISC loading and/or mRNA targeting. Pharmacologic formulation of miRNA mimics 
for systemic administration can result in severe immune toxicities.37 Cell-selective delivery of chemically-
stabilized, naked miRNA mimics is gaining attention with a success of siRNA delivery using hepatocyte-
specific GalNAc-conjugates38 and a recent study revisited folate as targeting moiety to miRNA delivery to 
breast and lung cancer cells.39  
Our previous studies focused on myeloid cell-selective delivery of oligonucleotides to disrupt 
immunosuppression in the tumor microenvironment. The conjugation of CpG ODNs with inhibitors of STAT3, 
a master immune checkpoint regulator, resulted in potent antitumor immune responses. While it seems 
counterintuitive, the SR/TLR9-mediated delivery strategy can be adapted for dampening excessive immune 
activity of myeloid cells in autoinflammatory diseases or myeloid malignancies. Unlike type-B CpG 
sequences, the type-A CpG ODNs are poor activators of NF-κB signaling and cytokines such as IL-6 and 
IL-10.40 While recent study showed that injections of CpG(A) alleviated severity of sepsis in mice by 
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reducing blood clotting,41 the control CpG(A)-scrRNA did not show anti-inflammatory activity in our 
experiments. The presence of functional miR-146a-5p guide strand in the CpG conjugate was key to the 
biological activity of this oligonucleotide. The more extensive chemical modifications of miR-146a guide 
strand impact its activity, likely interfering with unwinding of the duplex while in RISC.42 Importantly, even 
partial restoration of miR-146a-5p levels in target immune cells in vivo was sufficient for near complete and 
durable inhibition of target IRAK1 and TRAF6. The systemic administration of C-miR146a effectively 
reversed key features of the miR146a-deletion related to excessive NF-κB signaling in both mouse and 
human myeloid cells. Cytokine storm and CRS occur in response to various conditions from bacterial 
infections, antibody-based therapies to immunomodulatory drugs. In context of CAR T-cell cancer therapies, 
especially CD19-specific CAR T-cells, CRS is one of the most common and potentially fatal adverse effects. 
The lower incidence of CRS correlates with prolonged survival of patients receiving CAR-T therapy.43 
Despite the routine use of the IL-6 receptor antagonist (Tocilizumab), high-dose steroid hormones are 
frequently required to control severe CRS but at the same time potentially curbing antitumor efficacy of CAR 
T-cells.43,44 Hence, the need for more precise and safer immunomodulatory strategies addressing 
complexity of immune responses. Myeloid cell-selective miR-146a mimic acts at the nodal point of immune 
cell network, preventing release of cytokines driving CRS from monocytes and macrophages without 
interfering with CAR T-cell activity.12,15  
The simplicity and flexibility of the C-miRNA mimic design, adaptable to delivery of both miRNA mimics and 
anti-miRs, provides as opportunity for the development of miRNA therapeutics for immunomodulation 
and/or therapy of myeloproliferative diseases and leukemia. The pleiotropic effect of single miRNA on 
multiple protein targets benefits their potency and reduces development of drug resistance, while the 
myeloid cell-targeted delivery can improve safety of miRNA therapeutics. The growing list of myeloid cell-
specific anti-inflammatory miRNAs extends beyond miR-146a, including recently described miR-125b and 
miR-203b or tolerance-inducing miR-221 and miR-222.45,46 In addition to the immunoregulatory role, the 
miR-146a is well established tumor suppressor and the genetic loss of miR-146a or downregulation is 
common in MDS patients and in AML.47 MiR-146a replacement using SR/TLR9-targeted delivery provides 
therapeutic opportunity in MDS/AML patients. However, given the genetic instability of AML, C-miR146a 
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therapy could likely benefit from combination with targeting additional oncogenic or tumor suppressor 
miRNAs.47 The upregulation of oncogenic miR-155 is common in FMS-like tyrosine kinase 3 internal 
tandem duplication (FLT3-ITD)-associated AML.48 Noteworthy, miR-155 can potentially antagonize the 
inhibitory effects of miR-146a on NF-B in mouse myeloid cells.20 It is not known whether miR-155 plays 
similar role lessening tumor suppressive effect of miR-146a in human leukemia but our strategy can be 
easily adapted to delivery of anti-miR155 to AML cells and leukemia stem cells.49 Further studies should 
explore the possibility of personalizing miRNA mimic/antisense combinations to an AML patient-specific 
miRNA profile using the same SR/TLR9 delivery platform. The emerging CAR T-cell strategies for AML, 
such as CD123-specific CAR design underscore the potential to combine AML-specific CAR T-cells with C-
miR146a, thereby alleviating potential immunotoxicities as well as reducing AML cell survival.50 We believe 
that SR/TLR9-targeted delivery of miR-146a mimic provides an outline for development of miRNA 
therapeutics for a variety of inflammatory disorders and myeloid malignancies. 
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FIGURE LEGENDS 
Figure 1. Targeted delivery of miR-146a mimic to RISC/Ago2 complexes in myeloid cells. (A) The 
design of C-miRNA146a mimic conjugate; underlined: phosphorothioated nucleotides; “o”: C3 units of the 
carbon linker; green: 2’-O-methyl-modified nucleotide. (B) Serum stability of miR146a (left) and C-miR146a 
(right). Oligonucleotides were incubated in 50% human serum at 37°C for the indicated times and then 
resolved on 7.5M urea/15% PAGE gel. Shown is a representative result from one of three independent 
experiments; the band intensities were quantified, and the estimated oligonucleotide half-lives were 
indicated. (C) The intracellular uptake of C-miR146aCy3 compared to miR146aCy3 alone by primary human 
immune cells (monocytes: CD14+; mDCs: CD1c+; pDCs: CD303+; B cells: CD19+; and T cells: CD3+), 
mouse RAW264.7 macrophages, human MDSL and HL-60 leukemia, human Raji lymphoma and TAIL7 T-
cell leukemia cells. Cells were incubated for 1h with 100nM C-miR146aCy3 or miR146aCy3 without any 
transfection reagents, and the uptake was measured using flow cytometry. (D) The intracellular localization 
of C-miR146aCy3 or miR146aCy3 oligonucleotides (100nM/red) as visualized using confocal microscopy in 
RAW264.7 cells after 1h incubation. Hoechst33342 (blue) was used for nuclear counterstain. (E) The 
successful loading of miR146a into RISC/Ago2 by C-miRNA conjugate.  RAW264.7 or splenocytes isolated 
from miR-146a–/– mice were incubated for 1h with 1μM C-miR146a or miR-146a alone. The RNA-protein 
complexes were immunoprecipitated using anti-Ago2 or control IgG antibodies and the miR-146a levels 
were quantified using qPCR. The equal protein loading was confirmed with Western blotting. The data 
shown represent results from three independent experiments; shown are means±SEM.  
 
Figure 2. C-miR146a mimic targets upstream regulators of NF-κB signaling. (A) C-miR146a inhibits 
IRAK1 and TRAF6 expression through a sequence-dependent, on-target effect. HEK293T cells were 
incubated for 24h with 500nM C-miR146a, control C-scrRNA or miR-146a alone, and then transfected with 
wild-type or mutated IRAK1 or TRAF6 3’UTR-luciferase reporter and control Renilla luciferase plasmids. 
The reporter luciferase activities were evaluated after 48h. (B) Reduced protein levels of IRAK1 and TRAF6 
in C-miR146a-treated mouse macrophages and human leukemia cells. IRAK1 and TRAF6 protein levels 
were assessed using Western blot in RAW264.7 and MDSL cells after 48h incubation with 500nM of 
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indicated oligonucleotides. Shown are representative results; band intensities were quantified with 
normalization to β-actin as a loading control. (C) MiR146a mimic delivery prevents nuclear translocation of 
NF-B. RAW264.7 cells stably expressing p65-eGFP fusion protein were incubated overnight with 500nM 
C-miR146a or control C-scrRNA and then stimulated with 100ng/mL LPS for 4h. Translocation of NF-
B/p65 (green) into nuclei (blue) was visualized using confocal microscopy; (D) C-miR146a inhibits NF-κB 
DNA binding in target myeloid cells, RAW264.7 or MDSL. Cells were incubated with 500nM C-miR146a, C-
anti-miR146a or control C-scrRNA for 48h. The NF-κB DNA binding was assessed in nuclear extracts and 
verified using p65-specific antibody supershift. Representative blots (left/middle) and the quantification of 
band intensities combined from three experiments (right). (E-F) C-miR146a reduces transcriptional activity 
of NF-B in macrophages. RAW-Blue (E) or RAW264.7 (F) cells were incubated overnight with 500nM C-
miR146a or control C-scrRNA and then stimulated with 100ng/mL LPS for 4h. The expression of the NF-κB-
dependent reporter gene (E) or IL-6 secretion (F) were assessed using Quanti-Blue assay or ELISA, 
respectively. Shown are representative results obtained in three independent experiments; means±SEM.  
 
Figure 3. C-miR146a targets myeloid cell populations and restores miR-146a levels and activity in 
miR-146a–/– mice. (A, B) Dose-dependent biodistribution of miR-146a mimic in organs (A) and in bone-
marrow CD11b+ myeloid cells and CD11b– cells (B) of miR-146a-deficient mice. Mice were injected IV using 
various doses of C-miR146a and euthanized 3h later to assess miR-146a levels in bone marrow (BM), 
spleen, lymph nodes (LN), blood, and enriched BM CD11b+ myeloid cells and CD11b– cells using qPCR. (C) 
Biodistribution of systemically injected C-miR146a and miR-146a. C57BL/6 mice engrafted with 
Cbfb/Myh11/Mpl leukemia were injected IV with 5 mg/kg C-miR146aCy3 or miR-146aCy3 and euthanized 3h 
later. The percentages of Cy3+ cells in bone marrow were assessed using flow cytometry (T cells: CD3+, NK 
cells: NK1.1+, B cells: CD19+, ST-HSC: Lin–cKit+Sca1+Flt3–CD150–CD48–, LT-HSC: Lin–cKit+Sca1+Flt3–
CD150+CD48–, monocytes: CD11b+CD11c–, macrophages: CD11b+F4/80+, DCs: CD11b+CD11c+, MDSCs: 
CD11b+Gr1+, and AML cells: GFP+). Shown are results representative for two independent experiments; 
means ± SEM (n=3 mice/group). (D-E) Myeloid cell-selective delivery of miR-146a in vivo. miR-146a–/– or 
WT mice were injected IV with 5mg/kg C-miR146a and euthanized 3h later. miR-146a levels in BM and 
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splenocytes and enriched CD11b+ myeloid cells, CD19+ B-cells and CD3+ T-cells from spleen were 
assessed using qPCR and compared to the same populations in untreated WT mice. Shown are 
representative results obtained in three independent experiments; means±SEM (n=3). (F) Single injection of 
C-miR146a results in transient downregulation of IRAK1 and TRAF6 protein levels. miR-146a–/– mice were 
injected IV with 5 mg/kg C-miR146a and euthanized at indicated times. Protein levels of IRAK1 and TRAF6 
in bone marrow cells were assessed using Western blot and the quantified band intensities normalized to β-
actin were shown. Shown are results representative for two independent experiments. 
  
Figure 4. C-miR146a corrects the aberrant myeloproliferation and inflammatory responses in 
miR146a-deficient mice. (A-B) Reduced proliferation of miR-146a–/– bone marrow-derived macrophages 
(BMDM) treated with C-miR146a. Bone marrow cells from WT and miR-146a–/– mice were cultured in the 
presence of 50ng/ml M-CSF for 7 days and treated using 1µM C-miR146a or C-scrRNA. The cell 
proliferation (A) was measured using colorimetric XTT assay and the CSF1R expression on CD11b+F4/80+ 
cells (B) was quantified using flow cytometry. (C-E) Systemic C-miR146a injections reduced aberrant 
myeloproliferation of miR-146a–/– mice in vivo. 10 month old WT or miR-146a–/– female mice (n=4/group) 
were injected IV using 10mg/kg C-miR146a or PBS daily for two weeks and euthanized a day after the last 
injection. Percentages of splenic CD11b+Gr1+ (C), Ki67+CD11b+Gr1+ (D), and the CSF1R expression on 
macrophages (E) were analyzed using flow cytometry.  (F) Systemic injections of C-miR146a alleviate 
exaggerated response to endotoxin in miR-146a–/– mice. WT or miR-146a–/– mice were injected IV with 
5mg/kg C-miR146a or C-scrRNA daily for three days before LPS challenge (IP/1mg/kg). Blood was 
collected at the indicated times to analyze IL-6 and TNF-α levels using ELISA. (G-J) C-miR146a treatment 
restored tolerance to Listeria monocytogenes infection in mice with myeloid cell-specific miR146a-deletion. 
WT or miR-146afl/fl mice injected daily IV using 5 mg/kg C-miR146a or C-scrRNA were infected with L. 
monocytogenes on day 3 and euthanized on day 6. The liver bacterial load (G), the percentage of weight 
loss (H), plasma levels of IL-6 (I) and percentages of various hematopoietic cell populations in circulation (J) 
were assessed. Representative results from at least two independent experiments are shown; means±SEM 
(n=5/group).  
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Figure 5. Targeting monocytes using C-miR146a mimic alleviates cytokine release syndrome 
induced by CD19 CAR T-cells without compromising antitumor effects.  (A-B) C-miR146a does not 
affect cytotoxic activity of CD19 CAR T-cells against target leukemia cells. Mock- or CD19 CAR-transduced 
T cells were co-cultured at a 1:1:1 ratio with donor-matched CD14+ monocytes and target CD19+ Nalm6 B-
cell leukemia for 48h in the presence of 500nM C-miR146a or control C-scrRNA. Shown are the 
percentages of live CD19+ target cells (left) or CAR T-cells (right) vs. untreated control (A). The IL-1 and IL-
6 levels in cultured supernatants as measured using ELISA (B). Shown are results combined from four 
different PBMC donors. (C) The experimental design for in vivo studies on the CAR T-cell-induced CRS 
using xenotransplanted lymphoma model. SCID-Beige mice were engrafted with luciferase-expressing Raji 
lymphoma cells (IP) and after two weeks injected daily using 5mg/kg/IP of C-miR146a or PBS. 12.5x106 
mock or CD19 CAR T-cells were injected IP on day 18 before euthanizing mice on day 22. (D-E) Tumor 
progression was monitored using bioluminescent imaging (BLI): ROI, regions of interest; p/s, photons per 
second; means±SEM. (F) The intracellular miR-146a levels were measured using qPCR in CD11b+ myeloid 
and CD11b– non-myeloid cells derived from peritoneal lavage. (G) Serum human cytokine levels and mouse 
IL-6 and G-CSF were measured using ELISA after 24h from CAR T-cell transfer. Representative results 
from at least two independent experiments were shown as means±SEM (n=4). 
 
Figure 6. C-miR146a targets NF-κB signaling and inhibits progression of del(5q) MDS and AML. (A) 
Del(5q) HL-60 or MDSL cells or Flt3 mutation MV4-11 leukemia cells were treated in vitro using 500nM 
C-miR146a or C-scrRNA for 6 days and the percentages of live cells were assessed using flow cytometry. 
Representative results obtained from three independent experiments; means±SEM. (B-D) Systemic 
administration of C-miR146a extended survival of human HL-60 AML-bearing mice. NSG-SGM3 mice 
engrafted with disseminated HL-60-luc cells were injected daily IV using 10mg/kg C-miR146a or C-
scrRNA and leukemia progression was monitored using BLI (B), leukemia progression (C) and the Kaplan-
Meier survival curves (D). Shown are representative results from at least two independent experiments; 
means±SEM (n=10). (E) NF-κB pathway gene analysis in HL-60 AML-bearing mice after 10 injections of 
C-miR146a, C-scrRNA or PBS (n=3/group). Total RNA isolated from bone marrow was analyzed using RT2 
Profiler PCR Arrays. The clustergram of significantly (>1.5 fold) downregulated genes. (F) Low miR-146a 
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expression is associated with worse overall AML patients’ survival based on the TCGA dataset. The 
optimal cut-point was identified using Log-rank statistics in a survfit model. The log-rank test P value is 
shown. (G) Gene Set Enrichment Analysis in AML patients with high versus low miR-146a expression 
based on TCGA dataset with a NF-κB gene set from Gene Ontology (70 genes). Samples having both 
miRNA and mRNA expression data (n=151) were applied to this analysis. Normalized enrichment score 
and p-value are shown. (H) Standard boxplots were applied to visualize the distribution of log2-
transformed expression of IRAK1, NFKB1, and NFkB2 with the low and high miR-146a expression 
groups. ***P < 0.001; **P < 0.01.  
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